GLP-1 medicines are not right for everyone
The price for her dose of the compounded version is $329 monthly, compared to the brand name's list price of more than $1,000 per month
At the biostation, patients get more than just medicine
nejm.org/doi/full/10.10 Number 1 Top Cardiometabolic Story of 2023: Phase 2 trial with #retatrutide, a GIP-GLP-1-GCG receptor triple agonist, resulted in a mean weight reduction of 24.2% after 48 weeks
REDEFINE Phase 3 clinical program evaluating cagrilintide alone and with semaglutide 3,400+ Participants in the REDEFINE 1 trial across multiple countries Questions No, cagrilintide is not yet FDA approved
These conditions can cause a wide array of symptoms, ranging from blurry vision to complete vision loss